Aspirin

The selected 81-mg chewable and 325-mg delayed-release products relieve minor aches and pains. Bayer Genuine 325 mg also labels fever relief and specific minor pains. Enteric-coated Bayer has delayed action and is not intended for symptoms needing rapid relief. These OTC monograph products are not individual new-drug approvals for universal cardiovascular prevention.

USPSTF recommends an individual decision about starting low-dose aspirin for adults 40–59 with at least 10% estimated 10-year cardiovascular risk and no increased bleeding risk; net benefit is small. Do not initiate it for primary prevention at age 60 or older. This applies to people without known cardiovascular disease. For chronic coronary disease without an indication for oral anticoagulation, the 2023 AHA/ACC guideline recommends low-dose aspirin to reduce atherosclerotic events. Coronary stents, anticoagulation, prior bleeding, and other vascular diagnoses require an individualized antithrombotic plan.

These are the selected U.S. label directions for age 12 and older. Drink a full glass of water with each dose. Under 12, obtain a clinician’s direction rather than calculating an adult fraction. Avoid aspirin in children or teenagers with chickenpox or flu-like illness regardless of these dosing ages.

For selected primary-prevention patients who choose therapy, USPSTF considers 81 mg/day reasonable. For chronic coronary disease without an oral-anticoagulant indication, the AHA/ACC guideline recommends 81 mg/day (75–100 mg). These maintenance regimens are distinct from OTC analgesic directions. Suspected heart attack requires emergency medical care and the emergency clinician’s instructions; this focused reference does not provide an acute coronary loading protocol.

Use the least symptom dose needed within the package limits. Review pain beyond 10 days, fever beyond 3 days with a fever-labeled product, new symptoms, or swelling/redness. Follow the exact chewable, conventional, or delayed-release package; the delayed-release label explicitly warns that onset is slower. Cardiovascular duration and perioperative changes require the treating clinician’s plan.

OTC labels say not to use after allergy to aspirin or other pain relievers/fever reducers; ingredient allergy also excludes the chewable and delayed-release products. The selected chewable label additionally prohibits use for at least seven days after tonsillectomy or oral surgery unless a clinician directs otherwise. Active bleeding or major bleeding risk needs clinical assessment before a preventive regimen; it is not resolved by selecting an enteric-coated product.

The selected OTC Drug Facts labels have no prescription boxed warning. Their Reye syndrome, allergy, bleeding, pregnancy and overdose warnings still apply.

Stomach symptoms, bleeding, severe allergy or wheezing can occur. Ringing ears or reduced hearing calls for stopping and assessment. Suspected excess ingestion requires immediate medical help or Poison Control, even before symptoms appear. No home-induced vomiting or home detoxification regimen is supplied.

Anticoagulants, steroids and other NSAIDs increase the labeled gastrointestinal bleeding risk. Review prescribed antiplatelet combinations rather than adding OTC doses independently. The Drug Facts labels also direct clinician/pharmacist review of prescriptions for gout, diabetes or arthritis and clinician review with diuretics.

FDA describes interference with aspirin’s platelet effect. For a single 400-mg ibuprofen dose and immediate-release 81-mg aspirin, separation of ibuprofen at least eight hours before or at least 30 minutes after aspirin can minimize measured interference. This evidence does not establish a timing rule for enteric-coated aspirin, repeated ibuprofen regimens, or every NSAID, and clinical cardiovascular outcomes were not tested. Obtain a pharmacist/prescriber plan; spacing does not remove bleeding risk.

Consult the obstetric clinician. FDA advises avoiding NSAID self-use from 20 weeks because fetal renal injury and low amniotic fluid can occur; if needed at 20–30 weeks, use the lowest dose briefly and consider ultrasound after more than 48 hours. Avoid from 30 weeks because of ductus-closure risk. FDA exempts clinician-prescribed 81-mg aspirin for certain pregnancy conditions. The current chewable label mentions 20 weeks; Bayer labels retain last-three-month wording, so that older wording must not imply safety at 20–29 weeks. Breastfeeding requires professional review under all selected Drug Facts labels; no proven infant-safety claim is made.

Do not extrapolate adult OTC regimens below age 12. Reye syndrome restrictions apply to children and teenagers with viral illness. Older adults have greater bleeding risk; USPSTF’s recommendation against initiating primary prevention from age 60 is distinct from secondary prevention in established coronary disease. Reassess existing therapy with the clinician.

The OTC labels require clinician review for kidney disease or cirrhosis and supply no validated renal/hepatic dose-adjustment table. Do not treat a low-dose product as automatically appropriate in these conditions. Assess organ disease, bleeding risk, other NSAIDs and diuretics before selecting therapy.

Aspirin irreversibly inhibits platelet cyclooxygenase, decreasing thromboxane A2 generation and platelet aggregation. This explains the antiplatelet purpose; the analgesic/antipyretic effect is a separate reason for higher symptom doses. The mechanism here is taken from the aspirin-specific portion of a combination label, not from dipyridamole’s effects.

Aspirin is rapidly hydrolyzed to salicylate, which undergoes hepatic conjugation and renal elimination. Salicylate elimination becomes dose-dependent at greater exposure. These ingredient-level facts come from the aspirin subsection of the combination label; its absorption measurements are not asserted for these OTC tablets. The delayed-release product’s own label establishes its slower symptom action.

Confirm the indication, formulation, dose and other OTC medicines. For prevention, reassess cardiovascular benefit, age, bleeding history and concomitant anticoagulation/NSAIDs. Report black stools, blood in vomit, faintness, persistent stomach pain, tinnitus or hearing change promptly. No routine serum aspirin level or fixed laboratory schedule is specified by these OTC labels.

Read the dispensed Drug Facts label and avoid duplicate aspirin/NSAIDs in combination products. Keep out of children’s reach. Explain the difference between one daily preventive dose and multiple-tablet analgesic doses, the pregnancy exception’s prescribed scope, and the need to tell surgical/dental clinicians about therapy. Emergency symptoms or suspected overdose require immediate help.

Selected examples are Signature Select cherry-flavored 81-mg chewable tablets, NDC 21130-397-07 (36 tablets); Bayer Genuine 325-mg conventional coated tablets, NDC 0280-2000-10 (100 plus 24 promotional tablets in this label); and Bayer Safety Coated 325-mg delayed-release caplets. Conventional coating and enteric/delayed release are different. Appearance and package sizes vary.

This reference verifies 81-mg chewable, 325-mg conventional tablets and 325-mg delayed-release caplets. Other aspirin strengths, 81-mg enteric-coated brands, powders, rectal products and combinations require their own directions; these examples are not a substitution guide.

Selected chewable: 25°C, permitted excursions 15–30°C. The Bayer conventional and delayed-release labels say room temperature and instruct keeping the carton for full directions/warnings; follow the dispensed package. Preserve the chewable product’s requirement to chew/crush completely; do not assume it applies to another formulation.